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Abstract
Transcatheter aortic valve implantation (TAVI) has been proposed to treat older surgical high-risk patients with severe symptomatic aortic
stenosis. There are no data regarding short-term and long-term infectious complications in these patients. The objective of this study was to
deﬁne the incidence, aetiology and outcome of early and late infectious complications following TAVI compared with patients >65 years old
undergoing traditional surgical aortic replacement (SAR). This was a prospective observational study evaluating all consecutive patients who
underwent TAVI or SAR. Follow up was performed up to 1 year after the procedure of valve implantation. Fifty-one patients underwent
TAVI and were compared with 102 patients who underwent SAR. Compared with SAR patients, those who underwent TAVI had lower
incidence of early post-operative (11.7% vs 26.4%, p 0.04), intermediate (5.9% vs 17.6%, p 0.01) and late (7.8% vs 11.7%, p 0.03) infections.
Among SAR patients the most common infections were bloodstream infections, pneumonias, urinary tract infections and sternal wound
infections. Patients who underwent TAVI had a longer survival without infection (358 days vs 312.9, p 0.006). There were no signiﬁcant
differences in 12-month crude survival between the two study populations. Despite a high frequency of coexisting illnesses, patients
undergoing TAVI develop few infectious complications. TAVI appears to be a reasonable and safe option in high-risk patients with severe
symptomatic aortic stenosis.
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Introduction
Surgical aortic replacement (SAR) has been long considered
the standard of treatment for patients with severe symptom-
atic aortic stenosis, and is associated with better prognosis and
improvement in quality of life [1,2]. However, surgical valve
replacement may result in severe complications, especially in
elderly patients with multiple comorbidities. As a conse-
quence, up to 30% of patients with severe symptomatic aortic
stenosis do not undergo surgical intervention [3,4].
A novel approach, transcatheter aortic valve implantation
(TAVI), has been proposed to treat older surgical high-risk
patients with severe symptomatic aortic stenosis [5–7]. The
Placement of Aortic Transcatheter Valves (PARTNER) trial
was a randomized trial comparing TAVI with standard-of-care
therapies in high-risk patients with aortic stenosis. One-year
mortality outcomes from PARTNER found that TAVI was
superior to standard therapy in patients who could not
undergo surgery and not inferior to surgical replacement in
high-risk patients [8]. No clinical studies have analysed the
early and late infectious complications in patients undergoing
TAVI, with the exception of a recent study that evaluated only
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the post-operative infectious episodes during hospitalization
[9]. The aim of our study was to deﬁne the incidence, aetiology
and outcome of early and late (up to 1-year) infectious
complications in a group of consecutive patients who under-
went TAVI in our hospital, and to compare them with patients
>65 years old undergoing traditional SAR.
Methods
Patient sample and deﬁnitions
This prospective observational study evaluated all consecutive
patients who underwent TAVI from November 2009 to
November 2012 in the Policlinico Umberto I of Rome, a
1100-bed teaching hospital. Patients were qualiﬁed for a TAVI
procedure if they fulﬁlled the following criteria: presence of
severe symptomatic aortic valve stenosis (valve area ≤1 cm2),
with or without aortic valve regurgitation and either (i) age
≥75 years and a logistic EuroScore ≥20% or (ii) logistic
EuroScore <20% and at least one of the following criteria:
cirrhosis of liver, pulmonary insufﬁciency (FEV1 ≤ 1 L) or
porcelain aorta. The patient was considered suitable to
undergo a TAVI procedure if the inclusion criteria were met
as conﬁrmed by an interventional cardiologist, clinical cardi-
ologist, cardiac anaesthesiologist and a cardiac surgeon (local
heart team). Both currently commercially available devices, the
Edwards SAPIEN XT balloon-expandable prosthesis (Edwards
Lifesciences, Inc., Irvine, CA, USA; from January 2012) and the
Medtronic Core-Valve self-expanding device (Medtronic,
Minneapolis, MN, USA) were included. Only transfemoral
procedures were analysed.
The following parameters were collected for each patient:
demographics, clinical and laboratory ﬁndings, comorbidities,
microbiological data, duration of intensive care unit stay and
hospital stay, incidence of infections during hospitalization and
6 and 12 months after valve replacement, side-effects and
outcome (overall mortality and mortality attributable to
infection). To compare TAVI with SAR we included consec-
utive patients with an age ≥65 years undergoing SAR during
the same study period, with a 1 : 2 ratio. Patients were
excluded if they had an age <65 years or were lost to follow
up. The selection of this population of patients was based on
the need to create a homogeneous population to compare
with patients undergoing TAVI. All patients were treated in the
Heart Surgery Unit of our hospital. Intensive post-operative
assistance was the same for both groups.
Bloodstream infections, respiratory infections, urinary tract
infections and skin or soft tissue infections were deﬁned
according to the standard deﬁnitions of the Centers for Disease
Control and Prevention (CDC) [10]. Bloodstream infections,
including sepsis, severe sepsis and septic shock, were deﬁned
according to standard international criteria [11]. Bacteraemia
was deﬁned as the isolation of microorganisms from two or
more separate blood cultures with clinical evidence of infection,
and infective endocarditis was diagnosed according to the
modiﬁed Duke criteria [12,13]. An infection was deﬁned as: (i)
early post-operative if the infection occurred within 1 month
after the TAVI or surgical procedure, (ii) intermediate if the
infections occurred between 1 month and 6 months after the
procedure, and (iii) late if the infections occurred more than
6 months after valve replacement. All patients who underwent
SAR received perioperative prophylaxis with intravenous
cefazolin 2 g or acetyl-cefuroxime 2 g; patients with known
methicillin-resistant Staphylococcus aureus (MRSA) colonization
received intravenous prophylaxis with vancomycin 1 g. Screen-
ing for MRSA nasal colonization was performed before surgery,
and colonized patients were treated with topical mupirocin.
Follow up was performed for all patients, by use of
telephone interviews, evaluation during a new hospitalization,
or ambulatory visits, when possible. Echocardiographic follow
up was not mandatory, but was recommended at 1, 3, 6 and
12 months and then yearly. Data of all patients were entered
in an electronic database. Written consent was obtained from
the patient in all cases. The study was approved by the
independent ethics committee or institutional review board of
the participating centres.
Devices used
The Medtronic CoreValve prosthesis consists of a tri-leaﬂet
bioprosthetic porcine pericardial tissue valve, which is mounted
and sutured in a self-expanding nitinol stent frame. The proﬁle
size is 16–18 French with the current generation, three different
device sizes are available for different annulus dimensions: the
26-mm prosthesis for aortic annulus sizes from 20 to 23.5 mm,
the 29-mm prosthesis for annulus sizes from 23.5 to 27 mm and
the 31-mm prosthesis for annulus sizes from 27 to 29 mm. The
Edwards SAPIEN XT devices are balloon-expandable prosthe-
ses with a bovine pericardial tissue valve. Two device sizes were
available at the time of enrolment, the 23-mm device for annulus
sizes ranging between 18 and 21.5 mm and the 26-mm device
for annulus sizes from 21.5 to 24 mm. The access options
included only the transfemoral route. The proﬁle size of the
transfemoral vascular sheath was 16–20 Fr.
Statistical analysis
The results obtained were analysed using a commercially
available statistical software package (SPSS, version 20.0; SPSS
Inc., Chicago, IL, USA). To detect signiﬁcant differences
between groups, we used the chi-squared test or Fisher exact
test for categorical variables, and the two-tailed t test or
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Mann–Whitney U test for continuous variables, when appro-
priate. Statistical signiﬁcance was established at ≤0.05. All
reported p values are two-tailed. A multivariate analysis was
performed with a multiple logistic regression model; survival
curves for time-to-event variables were constructed with the
use of Kaplan–Meier estimates based on all available data and
were compared with the use of the log-rank test. For the
multivariable analyses, multiple imputations were used by
chained equation methods to accommodate missing baseline
variables [14]. The multivariable models included covariates
with a p value of <0.20 in univariate analyses. An additional
time-dependent covariate analysis (about age, length of
hospital stay, length of intensive care unit stay and other
time-dependent covariates) was performed to test the asso-
ciation of complications during TAVI or surgical replacement
with subsequent mortality.
Results
During the study period 51 patients underwent TAVI: 39
patients in the TAVI group underwent valve replacement with a
Medtronic CoreValveTM prosthesis, and 12 with a Sapien
EdwardsTM prosthesis. Patients undergoing TAVI were com-
pared with 102 patients who underwent standard SAR in the
same study period. Demographics, clinical features and out-
come of patients included in the two groups are summarized in
Table 1. Patients included in the SAR group had a lower median
age (71.2 years vs 77.9, p <0.001), a lower incidence of severe
heart failure (81.3% of patients vs 100%, p <0.001), and a lower
median Euroscore (18.8 vs 31.6, p <0.001); in contrast, patients
in the SAR group had a prolonged duration of hospitalization
from admission in the Heart Surgery Unit of our hospital
(34.2 days vs 24.6, p <0.001).
Overall, compared with SAR patients, those who under-
went TAVI had a lower incidence of early post-operative
(11.7% vs 26.4%, p 0.04), intermediate (5.9% vs 17.6%, p 0.01)
and late (7.8% vs 11.7%, p 0.03) infections. As reported in
Table 2, patients who underwent TAVI also had a lower
cumulative incidence of infections during the 1-year follow-up
period (25.5% vs 55.9%, p <0.001), and a longer survival
without infection (358 days vs 312.9, p 0.006). Fig. 1 shows
the estimated 12-month survival without infections by use of
Kaplan–Meier survival analysis.
The most common infections were bloodstream infections,
pneumonia, urinary tract infections and sternal wound infec-
tions. All types of infection, including bacteraemia (7.8% vs
18.6%, p <0.001), pneumonia (13.7% vs 19.6%, p 0.03) and
urinary tract infections (3.9% vs 5.8%, p 0.04), were less
common in TAVI patients than SAR patients. No patients of
the TAVI group developed endocarditis or surgical wound
infection. A sternal wound infection or a purulent mediastinitis
was diagnosed in 5.8% of SAR patients. As summarized in
Table 3, the most commonly isolated pathogens were MRSA
and methicillin-resistant Staphylococcus epidermidis. Both patho-
gens were signiﬁcantly more frequent in patients undergoing
SAR. Patients undergoing SAR also had a signiﬁcantly higher
frequency of Candida spp. bloodstream infections.
Univariate analysis of patients who died compared with
survivors is reported in Table 4. Multivariate analysis (see
TABLE 1. Clinical characteristics of transcatheter aortic






(n = 102) p
Median age (years) 79.3 71.2 <0.001
Men 31 (60.7%) 65 (63.7%) 0.72
Chronic obstructive
pulmonary disease
30 (58.8%) 54 (52.9%) 0.6
Heart failure (NYHA III/IV) 51 (100%) 83 (81.3%) <0.001
Diabetes mellitus 33 (64.7%) 65 (63.7%) 1.0
Neoplasm 13 (25.5%) 24 (23.5%) 0.84
Chronic liver disease 9 (17.6%) 14 (13.7%) 0.63
Presence of at least
two comorbidities
51 (100%) 82 (80.3%) <0.001
Renal replacement therapy 11 (21.5%) 15 (14.7%) 0.36
Chronic renal failure 21 (41.1%) 39 (38.2%) 0.72
Hospitalization in previous 90 days 28 (54.9%) 54 (52.9%) 0.86
Recent surgery (previous 30 days) 4 (7.8%) 7 (6.8%) 0.35
Intravascular devices at
time of infection
7 (13.7%) 12 (11.7%) 0.42
Immunosuppressive therapy 12 (23.5%) 8 (7.8%) 0.03
Euroscore (median) 31.6 18.8 <0.001
Median length of ICU stay (days) 2.4 4 0.003
Median length of hospital
stay (days)
24.6 34.2 <0.001
ICU, intensive care unit; NYHA, New York Heart Association.
Bold values are statistically signiﬁcant.
TABLE 2. Incidence of infections and outcome of transcath-






(n = 102) p
Early post-operative infections 6 (11.7%) 27 (26.4%) 0.04
Early post-operative mortality 11 (21.5%) 11 (10.7%) 0.08
Early post-operative mortality
due to infection
0 7 (6.8%) 0.09
Fever 1 (1.9%) 14 (13.7%) 0.02
Severe sepsis or septic shock 7 (13.7%) 32 (31.3%) 0.02
Intermediate infections 3 (5.9%) 18 (17.6%) 0.01
Intermediate mortality 7 (13.7%) 20 (19.6%) 0.58
Intermediate mortality
due to infection
1 (1.9%) 11 (10.7%) 0.02
Late infections 4 (7.8%) 12 (11.7%) 0.03
Late mortality 6 (11.7%) 12 (11.7%) 1.0
Late mortality due to infection 2 (3.9%) 6 (5.8%) 0.71




Survival (median, days) 254.2 279.1 0.28
All-cause mortality in
the study period
24 (47.1%) 43 (42.1%) 0.6
Bold values are statistically signiﬁcant.
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Table 5) found severe sepsis or septic shock, early post-oper-
ative infection, intermediate infection, heart failure and MRSA
aetiology as independent risk factors associated with all-cause
mortality. Fig. 2 shows the estimated 12-month crude survival
of the two study populations.
Discussion
To our knowledge this is the ﬁrst study comparing incidence,
aetiology and outcome of early and late infectious complications
in patients undergoing TAVI or SAR. The most important
ﬁnding of our study is that TAVI patients have a signiﬁcantly
lower incidence of early, intermediate and late infections, and a
reduced length of hospital stay. This ﬁnding is further supported
by the fact that patients undergoing TAVI are usually older, with
more comorbidities, and with a higher Euroscore than patients
undergoing SAR. Hence, TAVI appears as a safe procedure
associated with a low risk of infection.
Patients undergoing cardiac surgery are at higher risk of
post-operative infections, due to various factors: (i) the
prolonged duration of the surgical procedure is frequently
associated with multiple blood transfusions and post-operative
splanchnic hypoperfusion, leading to intestinal intramucosal
acidosis and increased intestinal mucosal permeability; (ii)
diabetic and obese patients have a high risk of sternal wound
infections, with risk of mediastinitis; (iii) patients undergoing
heart surgery and admitted to the intensive care unit
post-operatively have a high incidence of ventilator-associated
FIG. 1. Estimated 12-month survival without infections of the study
population using Kaplan–Meier survival analysis. TAVI, transcatheter
aortic valve implantation; SAR, surgical aortic replacement.






(n = 57) p
Site of infection
Bacteraemia 4 (30.7%) 19 (33.3%) 0.6
Endocarditis 0 4 (7%) <0.001
Surgical wound infections 0 8 (14%) <0.001
Pneumonia 7 (53.8%) 20 (35%) 0.03




1 (10%) 13 (27.6%) <0.001
Methicillin-resistant
Staphylococcus epidermidis
1 (10%) 9 (19.1%) <0.001
Others coagulase-negative
staphylococci
1 (10%) 0 0.07
Gram-negative pathogens
(all ESBL strains)
2 (20%) 3 (6.3%) 0.03
Candida spp. 0 3 (6.3%) 0.04
ESBL, extended spectrum b-lactamase; SAR, surgical aortic replacement; TAVI,
transcatheter aortic valve implantation.
Bold values are statistically signiﬁcant.






(n = 86) p
Median age (years) 74.7 73.9 0.9
Men 43 (64.2%) 53 (61.6%) 0.86
Chronic obstructive pulmonary disease 44 (65.6%) 40 (46.5%) 0.02
Heart failure (NYHA III/IV) 62 (92.5%) 72 (83.7%) 0.001
Diabetes mellitus 49 (73.1%) 49 (56.9%) 0.04
Neoplasm 21 (31.3%) 16 (18.6%) 0.08
Chronic liver disease 9 (13.4%) 14 (16.2%) 0.65
Presence of at least two comorbidities 63 (94%) 70 (81.3%) 0.03
Renal replacement therapy 18 (26.8%) 8 (9.3%) 0.005
Chronic renal failure 30 (44.7%) 30 (34.8%) 0.23
Hospitalization in previous 90 days 43 (64.2%) 39 (45.3%) 0.02
Recent surgery (previous 30 days) 6 (8.9%) 5 (5.8%) 0.38
Intravascular devices at time of infection 15 (22.4%) 4 (4.6%) 0.42
Immunosuppressive therapy 14 (20.9%) 6 (6.9%) 0.04
MRSA isolation 10 (14.9%) 4 (4.6%) 0.01
Fever 11 (16.4%) 4 (4.6%) 0.02
Severe sepsis or septic shock 31 (46.2%) 8 (9.3%) <0.001
TAVI 24 (35.8%) 27 (31.3%) 0.6
SAR 43 (64.1%) 59 (68.6%) 0.5
Euroscore (median) 28.9 22 0.004
Median length of ICU stay (days) 6.6 3.4 <0.001
Median length of hospital stay (days) 34.1 28.6 0.001
Early post-operative infections 23 (34.3%) 10 (11.6%) 0.001
Intermediate infections 15 (22.4%) 6 (6.9%) 0.009
Late infections 8 (11.9%) 8 (9.3%) 0.7
ICU, intensive care unit; MRSA, methicillin-resistant Staphylococcus aureus; NYHA,
New York Heart Association; SAR, surgical aortic replacement; TAVI, transcath-
eter aortic valve implantation.
Bold values are statistically signiﬁcant.
TABLE 5. Multivariate analysis of factors associated with
all-cause mortality
Variable p OR CI (95%)
Severe sepsis or septic shock <0.001 6.9 2.3–8.1
Infection during hospitalization 0.01 4.3 1.7–9.7
Intermediate infections (within 6 months
from hospitalization)
0.012 2.9 1.2–8.7
MRSA isolation 0.025 3.5 2.3–7.1
Heart failure (NYHA III/IV) <0.001 3.2 1.9–5.1
Hosmer–Lemeshow test, 0.829; Nagelkerke R2, 0.299.
MRSA, methicillin-resistant Staphylococcus aureus; NYHA, New York Heart
Association.
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pneumonia [15]; (iv) SAR patients usually require prolonged
antibiotic therapy, which facilitates intestinal overgrowth of
Candida spp. and selection of resistant pathogens; and (v)
several additional risk factors for infection are simultaneously
present, such as central venous catheter, total parenteral
nutrition, acute renal failure. Elderly patients usually have
multiple predisposing factors. The advantage of TAVI is that
patients do not undergo general anaesthesia, endotracheal
intubation or sternal incision, usually do not need post-oper-
ative respiratory support and are treated through a minimally
invasive transfemoral or trans-subclavian approach. The lower
invasiveness of TAVI probably explains the low incidence of
infection observed in our patients [16,17].
Patients undergoing SAR had a higher incidence of all types of
infection both in the early post-operative period and in the
follow-up period, and had a signiﬁcantly higher mortality from
infection. The SAR patients also had increased incidence of
severe sepsis and septic shock, and this complication is directly
related to a worse outcome [18]. Another important difference
between the two groups was the high frequency in SAR patients
of infections caused by multidrug-resistant pathogens, mainly
represented by MRSA and methicillin-resistant Staphylococcus
epidermidis [19–21], and by extended-spectrum b-lactam-
ase-producing gram-negative rods. In logistic regression analy-
sis, MRSA isolation was a factor independently associated with
death [22–25]. Three patients of the SAR group developed
candidaemia and one of these patients was diagnosed with
endocarditis due to Candida albicans about 9 months after
hospitalization. We have previously described late-onset endo-
carditis due to Candida spp., which becomes clinically evident
even several months from an initial episode of transient
candidaemia [26]. All the aforementioned factors might predis-
pose to the acquisition of multidrug-resistant pathogens and
also Candida spp. and the development of severe infections.
In our study, despite the presence of elderly and debilitated
patients, the overall mortality in the TAVI group was not
statistically different from that in SAR patients during the
1-year follow-up period. Patients included in the TAVI group
had a signiﬁcant lower mortality due to infection. Hence, the
lack of infections may be essential in the outcome of these
critically ill patients.
The study limitations should be acknowledged. First, the
small number of patients enrolled and the differences in some
baseline characteristics (mainly age) make a deﬁnitive compar-
ison of incidence of infections between the two groups
difﬁcult. Importantly, it is not a randomized trial. Finally, this
study represented the initial experience with TAVI in our
centre. Multiple reports suggest that subsequent device
generations and increased operator experience with TAVI
may improve outcomes.
In conclusion, TAVI is a new therapeutic option for high-risk
patients with severe aortic stenosis. Despite the high fre-
quency of coexisting illnesses in patients undergoing TAVI, the
frequency of infectious complication was very low. Our data
conﬁrm TAVI as a reasonable and safe option in inoperable or
high-risk patients with severe symptomatic aortic stenosis.
Further studies will be necessary to evaluate the cost-effec-
tiveness of TAVI compared with surgical aortic valve replace-
ment for other lower-risk patient populations.
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FIG. 2. Estimated 12-month survival for any cause of death of the
study population using Kaplan–Meier survival analysis. TAVI, trans-
catheter aortic valve implantation; SAR, surgical aortic replacement.
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